DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/05/2026 has been entered.
Claim Status
Claims 1, 4 and 9-16 are pending.
Claims 1, 4 and 16 are examined herein. (see response to argument below).
Claims 9-15 are withdrawn (see restriction/election in the previous action).
Priority
This application is filed on 11/03/2023 and no claims the benefit of domestic priority.
Information Disclosure Statement
6 IDS(s) are received on 1/25/2024, 4/02/2024, 6/28/2024, 6/16/2025, 5/27/2026 and 7/06/2026 have been considered unless marked with a strike through. No additional IDS(s) is/are provided since the last office action.
Response to Arguments
Applicants’ arguments/amendments filed on 10/05/2026, and in the amendments, claims 1, 4, and 16 are amended, and Claims 2-3, and 5-8 are cancelled. No new claims/matters have been added.
With respect to the claim objections have been fully considered and are persuasive. Therefore, the claim objections have been withdrawn.
With respect to the rejection of claims under 35 U.S.C 112(b) has been fully considered and are persuasive. Therefore, the rejection of claims under 35 U.S.C 112(b) has been withdrawn.
With respect to the rejection of claims under 35 U.S.C 103, the Applicant's arguments/ amendment have been considered and are persuasive, because claim 1 now requires that “a method for overcoming anticancer drug resistance of a patient being treated for thyroid cancer with an anticancer drug selected from lenvatinib or sorafenib, comprising co-administering said anticancer drug to said patient in a food or beverage, together with a compound represented by the Formula 1 or a pharmaceutically acceptable salt thereof”. Therefore, the previous rejection of 35 U.S.C 103 has been withdrawn.
With respect to the rejection of claims under 35 U.S.C 112(a), the Applicant's arguments for the rejection of 35 USC § 112 (a) has been considered but are moot in view of the new rejections for the amended claims 1, 4, and 16. The previous rejections of record are withdrawn in view of the amendment.
New Rejections
Claim Interpretation
The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art.
In view of dependent claims 4 and 16, and specification (paragraph [0046]-[0047], and [00120]), the phrase “in a food or beverage” in claim 1 is interpreted as requiring that the compound represented by Formula 1 be incorporated into a food or beverage and co-administered with the anticancer drug.
Claim Objections
Claim 1 is objected to because of the following informalities:
For the consistency with ‘Lenvatinib,’ the term ‘sorafenib’ should be written as “Sorafenib”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
The rejections under this section are made when the scope of the claimed subject matter is not clear. (See MPEP 2173)
Claims 1, 4, and 16 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claim 1, the definitions "A is N and B is -CH” and “B is N” render the claim indefinite because these definitions of B are inconsistent and mutually exclusive. Therefore, it is unclear whether B represents -CH or N in Formula 1 , rendering the scope of the claimed compound indefinite. Further, the variable B is defined twice, and one cannot tell whether they are both allowed, or not since each definition of “B” is a different set of atoms.
Claims 4 and 16 depend on claim 1, and these dependent claims incorporate the same indefinite Formula 1 definitions for the same reason. For purposes of the present examination, Formula 1 will be interpreted as encompassing the chemical structures of CKP1 and/or CKP2.
Regarding claim 16, the phrase "in an amount of 0.1 to 50 wt %” renders the claim indefinite because it is unclear whether the recited range applies to the compound of Formula 1 alone or the combined amount of the compound of Formula 1 and the anticancer drug. The specification (paragraph [0057]) describes the 0.1 to 50 wt % range for the compound of Formula 1 in a food composition, but the claim language in claim 16 does not clearly identify which component or components are subject to the limitation. Additionally, while claim 1 recites administration “in a food or beverage”, claim 16 uses the “with the food or beverage”. It is unclear whether claim 16 requires both active agents to be incorporated into the same food or beverage or permits separate administration of the anticancer drug with the food or beverage.
Claim Rejections - 35 USC § 112, enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 4, and 16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for experimental support for overcoming resistance to lenvatinib or sorafenib with Formula 1 compounds, does not reasonably provide enablement for the full scope of the claimed methods requiring administration in a food or beverage without undue experimentation. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
To be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by “undue experimentation,” the Federal Circuit has stated:
The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996).
The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited 8 factors: 1) the quantity of experimentation necessary; 2) the amount of direction or guidance provided; 3) the presence or absence of working examples; 4) the nature of the invention; 5) the state of the prior art; 6) the relative skill of those in the art; 7) the predictability of the art; and 8) the breadth of the claims.
These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108, 427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons:
Nature of the invention:
The invention is drawn to a method of overcoming resistance to lenvatinib or sorafenib in patients with thyroid cancer by co-administering a compound of Formula 1 or a pharmaceutically acceptable salt thereof in a food or beverage with the anticancer drug.
Breadth of the claims:
Claim 1 is broadly encompasses administration in food or beverages without limiting their composition, quantity, or preparation conditions. Claim 4 further recites co-administration involving a pharmaceutically acceptable carrier and claim 16 additionally specifies a concentration of 0.1-50 wt% based on the total weight of the food or beverage. Thus, the claims encompass a wide range of food and beverage formulations, including formulations having different physicochemical properties that may affect drug delivery and absorption.
Level of ordinary skill in the art:
A person of ordinary skill in the art would have knowledge of pharmaceutical formulation, pharmacokinetics, and cancer pharmacology, including experience with oral drug administration and food-drug interactions. Such a person would be familiar with conventional formulation methods and would recognize the effects of different food or beverage vehicles on drug performance.
State of the prior art and predictability in the art:
The effects of incorporating medications directly into food or beverages are formulation dependent and may be difficult to predict. Yin et al. ( J. Clin. Pharmacol. 51(11), 1580-6, pub’d 06/28/2011) studies that the oral anticancer drug nilotinib administrated by dispersing capsule contents into yogurt or applesauce (abstract). The study reports that administration in yogurt increased nilotinib’s maximum plasma concentration (Cmax) by approximately 31% compared with intact capsules, whereas administration in applesauce resulted in comparable bioavailability (discussion section). Thus, this study shows that different food vehicles produced different pharmacokinetic outcomes for the same anticancer drug. Martir et al. (AAPS PharmSciTech., 21(7), 287, 10/15/2020) evaluates dissolution of montelukast and mesalazine formulations administered with different food and beverage vehicles (abstract). The study shows that drug dissolution is significantly affected by the administration vehicle and the interval between mixing and administration (Figs. 2 and 4, and results and discussion section). Martir supports that the physicochemical properties of food or beverage vehicles may influence drug performance. Although Yin and Martir do not establish the claimed combination, they establish that incorporating a medication into food or beverages may alter its dissolution or systemic exposure in a vehicle dependent manner, and support relevant unpredictability in the claimed administration method.
Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, “the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.” See In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).
The amount of directions provided and working examples:
The specification describes food compositions containing Formula 1 compounds, including beverages, gums, teas, vitamin complexes, powders, granules, tablets, capsules, confectionery, cakes, bread, etc. (paragraph [0056]). It also identifies conventional food ingredients and discloses a concentration range of 0.1-50 wt% (paragraph [0057]). The specification further provides experimental evidence supporting the anticancer activity of Formula 1 compounds in combination with lenvatinib or sorafenib (paragraph [00148]-[00165]).
However, the working examples do not demonstrate administration of the claimed drug combination incorporated into a food or beverage. In addition, the specification does not provide formulation specific guidance regarding how different food or beverage vehicles affect the stability, dissolution, absorption, or therapeutic exposure of the co-administered agents. Although conventional oral formulations are described, the specification does not establish how therapeutically effective exposure is maintained across the broad range of food and beverage vehicles encompassed by the claims.
See MPEP 2164.02 (“Compliance with the enablement requirement of 35 USC 112, first paragraph, does not turn on whether an example is disclosed ... Lack of a working example, however, is a factor to be considered, especially in a case involving an unpredictable and undeveloped art.”).
Quantity of experimentation needed to use the invention based on the content of the disclosure:
The quantity of experimentation needed is undue experimentation. One of skill in the art would need to evaluate the effects of different food or beverage vehicles on the stability, dissolution, and absorption of the administered compounds. Such experimentations would be necessary to identify administration conditions that provide sufficient therapeutic exposure to overcoming resistance to lenvatinib or sorafenib.
A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.
Genentech Inc. v. Novo Nordisk A/S (CAFC) 42 USPQ2d 1001, states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”.
Claim Rejections - 35 USC § 112 written description
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 4 and 16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed by applicants. (see MPEP 2163.02)
An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed. (Emphasis added)
Further, the MPEP states that for a broad generic claim, the specification must provide adequate written description to identify the genus of the claim. (see MPEP 2161.01)
For instance, generic claim language in the original disclosure does not satisfy the written description requirement if it fails to support the scope of the genus claimed. Ariad, 598 F.3d at 1349-50, 94 USPQ2d at 1171 ("[A]n adequate written description of a claimed genus requires more than a generic statement of an invention’s boundaries.") (citing Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1405-06); Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 968, 63 USPQ2d 1609, 1616 (Fed. Cir. 2002) (holding that generic claim language appearing in ipsis verbis in the original specification did not satisfy the written description requirement because it failed to support the scope of the genus claimed); Fiers v. Revel, 984 F.2d 1164, 1170, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) (rejecting the argument that "only similar language in the specification or original claims is necessary to satisfy the written description requirement").
As set forth in the en banc decision in Ariad Pharmaceuticals Inc. v. Eli Lilly and Company, 94 USPQ2d 1161 (Fed. Cir. 2010) at 1171, the court stated as follows:
We held that a sufficient description of a genus instead requires the disclosure of either a representative number of species falling within the scope of the genus or structural features common to the members of the genus so that one of skill in the art can “visualize or recognize” the members of the genus. Id. At 1568-69. We explained that an adequate written description requires a precise definition, such as by structure, formula, chemical name, physical properties, or other properties, of species falling within the genus sufficient to distinguish the genus from other materials. Id. At 1568 (quoting Fiers v. Revel, 984 F.2d 1164, 1171 [25 USPQ2d 1601] (Fed. Cir. 1993)). We have also held that functional claim language can meet the written description requirement when the art has established a correlation between structure and function. See Enzo, 323 F.3d at 964 (quoting 66 Fed. Reg. 1099 (Jan. 5, 2001)). But merely drawing a fence around the outer limits of a purported genus is not an adequate substitute for describing a variety of materials constituting the genus and showing that one has invented a genus and not just a species.
Claims 1, 4, and 16 are directed to a method for overcoming anticancer drug resistance in patients with thyroid cancer by co-administering a compound of Formula 1 with lenvatinib or sorafenib in a food or beverage. Claim 16 further recites an amount of 0.1 to 50 wt% based on the total weight of the food or beverage.
The specification discloses certain aspects of the claimed invention. For example, the specification describes 1) a food composition for co-intake with an anticancer drug (paragraph [0008]); 2) identifying various food compositions, including beverages, gums, teas, powders, and bread (paragraph [0056]); 3) a Formula 1 compound may be incorporated into a food composition at 0.1 to 50 wt% (paragraph [0057]); and 4) combination therapy with sorafenib or lenvatinib and provides cell based and mouse xenograft data supporting the anticancer effects of the combination (paragraphs [00144]-[00147]). However, the specification does not disclose specific food or beverage formulations used to administer the claimed combination therapy. In addition, the specification also does not provide formulation specific information concerning the dissolution, stability, or systemic exposure of the compounds when administered in the disclosed food or beverage vehicles.
The specification itself acknowledges that appropriate drug dosing may depend on several factors, including the patient’s diet, the route and timing of administration, and the particular drug combination (paragraph [0045]).Nevertheless, although the specification broadly identifies various food and beverage formulations, it does not provide corresponding technical information addressing the effects of these different administration vehicles on the claimed combination therapy.
As discussed above in the “Claim Rejections - 35 USC § 112, enablement”, Yin and Martir support that food and beverage vehicles may influence drug dissolution and systemic exposure. Thus, they show the unpredictability associated with administering drugs in different food or beverage vehicles which also supports the lack of structure-function correlation between molecules when dosed with specific foods much less all food or beverages.
While this specification discloses general concepts of food compositions and resistance overcoming activities for the combination therapy under investigation, it does not provide specific formulations, experimental results, or other technical descriptions characterizing the claimed resistance overcoming method when the compounds are administered into the various food or beverage vehicles included in the claims. The vehicle dependent variability shown by Yin and Martir further raises a question as to whether the general food composition disclosure reasonably conveys possession of the full scope of the claimed therapeutical method. Furthermore, disclosed “an amount of 0.1 to 50 wt% for the Formula 1 compound in a food composition” in the specification does not describe this range as the combined amount of the Formula 1 compound and lenvatinib or sorafenib, as potentially required by claim 16.
As set forth in the en banc decision in Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1340, 94 USPQ2d 1161, 1167 (Fed. Cir. 2010), to satisfy the written description requirement, the specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention at the time of filing. Specifically, the specification must describe the claimed invention in a manner understandable to a person of ordinary skill in the art in a way that shows that the inventor actually invented the claimed invention at the time of filing. Id.; Ariad, 598 F.3d at 1351, 94 USPQ2d at 1172. (see MPEP 2161.01).
Accordingly, while disclosed food compositions and experimental support for the combination therapy in the specification, the disclosure does not adequately establish possession of the claimed resistance overcoming method across the full scope of the recited food or beverage administration embodiments at the time of filing.
Conclusion
Claims 1, 4, and 16 are rejected.
Claim 1 is objected to.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEONG JONG KIM whose telephone number is (571)272-6918. The examiner can normally be reached 7:00am-3:30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A. Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEONG JONG KIM/Examiner, Art Unit 1621
/CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621